Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy)

M Tahara, Masahiro Tahara, Tahara M, Tetsu Matsuoka, T Matsuoka, Matsuoka T, Yokoi T, T Yokoi, Takeshi Yokoi, Tasaka K, K Tasaka, Keiichi Tasaka, Hirohisa Kurachi, H. Kurachi, Kurachi H, Y Murata, Murata Y, Yuji Murata
Fertility and sterility · 2000 · vol. 73(4) , pp. 799–804 · doi:10.1016/s0015-0282(99)00636-6 · PMID:10731543 · W2132722874
RCT OA: closed CC0 ⤵ 31 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-06 ⓘ

This pilot study investigated the efficacy of a "draw-back" therapy for endometriosis, involving a decreasing dosage of nafarelin, a gonadotropin-releasing hormone agonist.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To evaluate the efficacy of half-dose GnRH agonist therapy for endometriosis. DESIGN: Prospective, longitudinal pilot study. SETTING: Osaka University Hospital. PATIENT(S): Patients with symptomatic endometriosis. INTERVENTION(S): Fifteen patients were randomized to receive either full-dose nafarelin treatment (200 microgram b.i.d.) for 24 weeks (n = 7) or full-dose nafarelin treatment for 4 weeks followed by half-dose nafarelin treatment (200 microgram daily) for 20 weeks (n = 8). MAIN OUTCOME MEASURE(S): Clinical symptoms and the results of physical examinations. Serum E(2) and carcinoma antigen 125 (CA125) levels, lipid profiles, and urinary levels of the N-telopeptide of type I collagen. Bone mineral density of the lumbar spine. RESULT(S): Subjective and objective manifestations of endometriosis were decreased to a similar extent in both study groups. Adverse effects were markedly reduced with half-dose administration. In the half-dose group, the mean serum E(2) level was significantly suppressed by 4 weeks of treatment with full-dose nafarelin and remained at approximately 30 pg/mL with half-dose nafarelin. Loss of bone mineral density was significantly less with half-dose treatment. CONCLUSION(S): Half-dose administration of nafarelin after pituitary down-regulation with full-dose nafarelin ("draw-back" therapy) is a new protocol for the treatment of endometriosis that is effective and associated with fewer adverse effects.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Hormones Nafarelin Administration, Intranasal Administration, Intranasal Bone Density Bone Density Bone Density CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen Collagen Collagen Collagen Collagen Dizziness Dizziness Dizziness Dose-Response Relationship, Drug

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (27)

Cited by (31)

Source provenance

europepmc
last seen: 2026-10-12T06:17:10.165071+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T20:59:21.759586+00:00
unpaywall
last seen: 2026-08-12T06:43:03.944938+00:00
License: CC0 · commercial use OK